The Diagnostic Value of Circulating Stanniocalcin-1 Mrna in Non-Small Cell Lung Cancer

Yu-Zhen Du,Xiao-Hua Gu,Li,Feng Gao
DOI: https://doi.org/10.1002/jso.21948
2011-01-01
Journal of Surgical Oncology
Abstract:Background and Objectives: Previous studies have suggested that the aberrant expression of Stanniocalcin-1 (STC1) occurs in tumor cells. In this study, we explored whether the circulating STC1 mRNA is a promising biomarker in the peripheral blood in patients with non-small cell lung cancer (NSCLC).Methods: The level of circulating STC1 mRNA was determined with a sensitive quantitative real-time reverse transcription PCR assay. and the data were analyzed by the statistical methods of one-way ANOVA, Mann-Whitney-Wilcoxon U-Test, and Receiver operating characteristic (ROC) curve analysis.Results: The level of circulating STC1 mRNA in patients with NSCLC was significantly higher than in patients with benign pulmonary disease (P < 0.001) or healthy volunteers (P < 0.001). Higher levels of circulating STC1 mRNA were associated with more advanced tumor stages and histological subtypes. Using a cutoff of 0.055, the sensitivity and specificity of STC1 mRNA levels to differentiate between patients with NSCLC and patients with benign pulmonary diseases was 66.7 and 90.9%, and it was 63.7 and 99.8% for patients with NSCLC and healthy volunteers, respectively.Conclusions: These findings support our hypothesis that circulating STC1 mRNA is a promising biomarker in the peripheral blood. J. Surg. Oncol. 104:836-840, 2011 (C) 2011 Wiley Periodicals, Inc.
What problem does this paper attempt to address?